Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors

Overview of attention for article published in JCO Precision Oncology, December 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 2 news outlets
twitter: 29 X users

facebook: 2 Facebook pages

Readers on

mendeley: 74 Mendeley

So far, Altmetric has seen 29 X posts from 29 X users, with an upper bound of 117,056 followers.

RT @ny1972_47: $tril 621 IT raises patients' ICAM: Increase M1, NK, deplete platelets to lower Treg https://t.co/7zz6Hy7oDs https://t.co/…

$tril 621 IT raises patients' ICAM: Increase M1, NK, deplete platelets to lower Treg https://t.co/7zz6Hy7oDs https://t.co/zcn5LuM8Ty

Multiple #cancer types have a mutational burden threshold that can predict patient responses to #immune checkpoint blockade: https://t.co/rdx1JkQlag via @ASCO @StrandLife @FoundationATCG #immunotherapy Image credit: Panda et al 2017 https://t.co/DRVGJgGxYI

Identifying a mutational burden threshold as a potential biomarker to immune checkpoint rx in solid tumors https://t.co/6gvPlOKKJu

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 25 additional X posts.